ArticleBMC cancer2022

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.

Soo Jin Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.